Comparative analysis of Hashimoto's and Riedel's thyroiditis morphology and immunohistochemistry

Gvianishvili, Tamuna; Gogiashvili, L; Chkhobadze, M

doi:10.1530/endoabs.63.p376

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the rarity of IgG4-RTD, a limited number of clinical studies are reported so far, addressing distinct entities among the condition [ 53 , 77 ] ( Table 5 ).…”

Section: Discussionmentioning

confidence: 99%

“…We also mention one study on 62 specimens after thyroidectomy that identified nine patients with RT. While IgG4 profiling was not available, other features such as positive stromal TTF-1, S100 protein (neuroectodermal cells), and lack of tumor markers such as CD56 and p63 were found to be distinctive in RT [ 77 ].…”

Section: Discussionmentioning

confidence: 99%

“…Table 5. Studies addressing the components of IgG4-RTD, including RT [53,77]. One study from Korea (between 2017 and 2021) included five patients with IgG4-RTD (two cases with IgG4-RT and three subjects with IgG4-mediated Hashimoto's thyroiditis).…”

Section: Non-rt Entities Among the Spectrum Of Igg4-related Thyroid D...mentioning

confidence: 99%

See 2 more Smart Citations

Reshaping the Concept of Riedel’s Thyroiditis into the Larger Frame of IgG4-Related Disease (Spectrum of IgG4-Related Thyroid Disease)

Cârșote

Nistor

2023

Biomedicines

View full text Add to dashboard Cite

Recently, Riedel’s thyroiditis (RT) was assimilated into the larger spectrum of immunoglobulin IgG4-related disease (IgG4-RD) in addition to a particular frame of IgG4-related thyroid disease (IgG4-RTD), underlying IgG4-RT, IgG4-associated Hashimoto’s thyroiditis (and its fibrotic variant), and IgG4-related Graves’s disease. Our objective was to overview recent data on RT, particularly IgG4-RD and IgG4-RTD. The case and study– sample analysis (2019–2023) included 293 articles and selected 18 original studies: nine single case reports (N = 9, female/male = 2/1, aged: 34–79 years, 5/9 patients with serum IgG4 available data, 2/5 with high serum IgG4) and four case series (N = 21; 4/5 series provided data on IgG4 profile, 3/21 had serum IgG4 assays, and 2/3 had abnormally high values). IgG4-RD and thyroid findings were analyzed in three cohorts (N = 25). Another two studies (N = 11) specifically addressed IgG4-RTD components. On presentation, the patients may have hypothyroidism, transitory thyrotoxicosis, goiter, long-term history of positive anti-thyroid antibodies, and hypoechoic ultrasound thyroid pattern. The 5-year analysis (N = 66) showed the rate of serum IgG4 evaluation remained low; normal values do not exclude RT. Mandatory histological and immunohistochemistry reports point out a high content of IgG4-carrying plasma cells and IgG4/IgG ratio. Unless clinically evident, histological confirmation provides a prompt indication of starting corticoid therapy since this is the first-line option. Surgery, if feasible, is selective (non-responders to medical therapy, emergency tracheal intervention, and open/core needle biopsy). Current open issues are identifying the role of serum IgG4 assays in patients with IgG4-RD, finding out if all cases of RT are IgG4-mediated, applying IgG4-RTD criteria of differentiation among four entities, and providing an RT/IgG4-RTD guideline from diagnosis to therapy. It remains that the central aim of approaching RT in daily practice is the early index of suspicion in order to select patients referred for further procedures that provide enough histological/immunohistochemistry material to confirm RT and its high IgG4 burden.

show abstract

“…Due to the rarity of IgG4-RTD, a limited number of clinical studies are reported so far, addressing distinct entities among the condition [ 53 , 77 ] ( Table 5 ).…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%